Welcome to our dedicated page for Apollomics SEC filings (Ticker: APLMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Apollomics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Apollomics's regulatory disclosures and financial reporting.
Apollomics Inc. director Huang Ya-Chi filed an initial ownership report showing a holding of restricted stock units tied to the company’s Class A Ordinary Shares. The filing reflects 2,000 restricted stock units, vesting in four installments of 500 shares each during 2026. Each unit represents the right to receive one Class A Ordinary Share.
Apollomics Inc. director TSAI HSIEN-SHU reported an initial holding of restricted stock units that are linked to the company’s Class A Ordinary Shares. The position covers restricted stock units tied to 2,000 underlying Class A Ordinary Shares held directly.
According to the footnotes, these restricted stock units vested with respect to 500 shares upon grant on February 9, 2026, with an additional 500 shares scheduled to vest on each of March 15, 2026, June 15, 2026 and September 15, 2026. Each unit represents a contingent right to receive one Class A Ordinary Share.
Apollomics Inc. director Jan Chen-Huan reported initial beneficial ownership of 2,000 Restricted Stock Units (RSUs), each tied to one Class A Ordinary Share. The RSUs vested with respect to 500 shares on February 9, 2026, with additional 500-share tranches scheduled on March 15, 2026, June 15, 2026 and September 15, 2026. Each RSU represents a contingent right to receive one Class A Ordinary Share, and the position is held directly.
Apollomics Inc. director and COO Chen Yi-Kuei filed an initial Form 3 reporting his equity holdings. He directly holds restricted stock units covering 20,000 Class A Ordinary Shares, vesting in four installments of 5,000 shares each during 2026. Each unit represents the right to receive one share. Through Maxpro Investment Co., Ltd., he is attributed 101,248 Class A Ordinary Shares and warrants exercisable for 3,823 Class A Ordinary Shares at an adjusted exercise price of $1,150.00 per full share, or $11.50 per warrant. He disclaims beneficial ownership of the Maxpro-held securities except to the extent of his pecuniary interest.
Apollomics Inc. disclosed initial holdings for Chief Financial Officer Lin Peter Kuan-How, showing 40,000 Restricted Stock Units tied to Class A Ordinary Shares. The RSUs vest in stages: 10,000 shares vested upon grant on February 9, 2026, with an additional 10,000 vesting on each of March 15, 2026, June 15, 2026 and September 15, 2026. Each RSU represents a contingent right to receive one Class A Ordinary Share, and the position is reported as directly owned.
Apollomics Inc. disclosed on a Schedule 13D that Hung-Wen (Howard) Chen and his wholly owned vehicle, King Regent Management Limited, together hold 896,362 Class A ordinary shares, representing 41.8% of the issuer's outstanding Class A shares (2,146,151 shares outstanding as disclosed). The holdings comprise 133,334 shares directly held by Mr. Chen and 763,028 shares held by King Regent. The filing amends a prior Schedule 13G and notes that Mr. Chen is Chairman and CEO; King Regent is a private investment holding company wholly owned by him. The transaction source is identified as PIPE subscription agreements executed on September 2, 2025, and the filing includes a joint filing agreement as an exhibit.
Apollomics Inc. Schedule 13G/A filed by Maxpro Investment Co., Ltd discloses that the reporting person beneficially owns 105,071 Class A ordinary shares, representing 4.90% of the Class A shares outstanding based on 2,146,151 shares. The total includes 101,248 currently outstanding Class A shares and 3,823 Class A shares issuable upon exercise of warrants exercisable within 60 days of this filing. The filing states that on September 3, 2025 the issuer completed a private placement of 1,042,803 Class A shares, after which Maxpro ceased to be a beneficial owner of more than 5% of the Class A shares; this amendment is an exit filing reflecting that change.
Apollomics Inc. reports major governance and leadership changes following a September 4, 2025 board meeting. The board appointed Yi-An Chu and Chen-Huan (Jack) Jan as new independent directors, bringing the board to seven members, five of whom are independent. The board also reconstituted key committees: the audit committee now includes Po-Jen Hsueh, Hsien-Shu Tsai (chairman), and Yi-An Chu; the compensation committee includes Moses Chen (chairman), Hsien-Shu Tsai, and Yi-An Chu; and the nominating and corporate governance committee includes Moses Chen, Po-Jen Hsueh, and Chen-Huan Jan (chairman).
The board named Hung-Wen (Howard) Chen as Chairman and Chief Executive Officer, appointed Yi-Kuei Chen as Chief Operating Officer, and Peter Lin as Chief Financial Officer, each bringing extensive experience in biotechnology, technology, finance, and private equity. The filing also corrects prior disclosure by stating that, following issuance of PIPE shares, Howard Chen and his affiliates beneficially own approximately 42% of Apollomics’ outstanding Class A ordinary shares, while Maxpro Investment Co., Ltd. and its affiliates beneficially own approximately 4.9%.
Apollomics Inc. filed a Form 6-K reporting biographical details for Po-Jen Hsueh and attaching an exhibit reference to a PIPE Subscription Agreement dated September 2, 2025. The filing states Mr. Hsueh has over 15 years of experience in operations, finance, and business development in the biopharmaceutical sector, including roles as COO of ACT Genomics and prior work at TaiGen Biotechnology where he participated in multiple financing rounds that together raised $114 million USD. The registrant also notes it will furnish omitted schedules and exhibits to the SEC upon request. The report is signed by Howard Chen, Chairman, dated September 3, 2025.
Apollomics Inc. reported that, due to its cash position, it is terminating all U.S. employees, including its Chief Executive Officer, Dr. Guo-Liang Yu, and Chief Financial Officer, Dr. Matthew Plunkett, effective August 29, 2025. This indicates a severe reduction of U.S. operations and leadership.
The company also stated that it expects to discontinue all activities related to its SPARTA clinical trial as soon as possible, signaling a shutdown of this development program. In addition, Apollomics has called an Extraordinary General Meeting of Shareholders for September 4, 2025, to seek shareholder approval for winding up the company, which would effectively bring its corporate existence to an end if approved.